Identifying patients at risk of progression to B cell malignancies and developing targeted therapies to eliminate the disease before it progresses

About the Ghobrial Lab ​
​Our mission: At the forefront of cutting-edge research, the Ghobrial Lab is spearheading Multiple Myeloma research. With unwavering commitment, we aspire to revolutionize the landscape of early detection and interception.  
 
Our team is devoted to identifying individuals at risk of B cell malignancies from precursor conditions such as Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) and developing targeted therapies to eliminate the disease before it progresses. 

We aim to identify the mechanisms of progression by analyzing the genetic, epigenetic, and immune alterations that govern the course multiple myeloma, ultimately striving towards a future where individuals live free from the burden of cancer.  

​Our Research Includes: 
  • Identifying factors that regulate disease progression in patients with MGUS/SMM to overt MM.
  • Understanding progression risk and identifying patients with precursor disease who would benefit most from early intervention.
  • Identifying novel immunotherapy targets and strategies in MM and MGUS/SMM.
  • ​Mechanisms of early cell dissemination and clonal heterogeneity.
  • The use of circulating tumor cells and cell-free DNA as disease biomarkers.
  • Defining the role of the bone marrow niche in regulating clonal evolution and disease progression.
  • Identifying novel biomarkers of disease progression in precursor hematological malignancies. 
  • Examining the cell-cell interactions of plasma cells in MM.
  • Therapeutic targeting of the bone marrow niche and interception of disease progression in myeloma.
  • Examining novel targets in clinical trials in Multiple Myeloma and Waldenstrom Macroglobulinemia (WM). 
  • The role of the bone marrow niche in regulating drug resistance in MM.